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H I G H L I G H T S
• Odds of prescription pain reliever misuse declined with abuse-deterrent OxyContin.
• Odds of heroin initiation declined with abuse-deterrent OxyContin.
• No evidence that the odds of heroin use changed due to the OxyContin reformulation.
A R T I C L E I N F O
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A B S T R A C T
The introduction of abuse-deterrent OxyContin in 2010 was intended to reduce its misuse by making it more
tamper resistant. However, some studies have suggested that this reformulation might have had unintended
consequences, such as increases in heroin-related deaths. We used the 2005–2014 cross-sectional U.S. National
Survey on Drug Use and Health to explore the impact of this reformulation on intermediate outcomes that
precede heroin-related deaths for individuals with a history of OxyContin misuse. Our study sample consisted of
adults who misused any prescription pain reliever prior to the reformulation of OxyContin (n = 81,400). Those
who misused OxyContin prior to the reformulation were considered the exposed group and those who misused
other prescription pain relievers prior to the reformulation were considered the unexposed group. We employed
multivariate logistic regression under a difference-in-differences framework to examine the effect of the re-
formulation on five dichotomous outcomes: prescription pain reliever misuse; prescription pain reliever use
disorder; heroin use; heroin use disorder; and heroin initiation. We found a net reduction in the odds of pre-
scription pain reliever misuse (OR:0.791, p < 0.001) and heroin initiation (OR:0.422, p = 0.011) after the
reformulation for the exposed group relative to the unexposed group. We found no statistically significant effects
of the reformulation on prescription pain reliever use disorder (OR: 0.934, p = 0.524), heroin use (OR:
1.014p = 0.941), and heroin use disorder (OR: 1.063, p = 0.804). Thus, the reformulation of OxyContin appears
to have reduced prescription pain reliever misuse without contributing to relatively greater new heroin use
among those who misused OxyContin prior to the reformulation.
1. Introduction
Opioid misuse continues to be a significant public health concern in
the United States. In 2015, approximately 12.5 million people had used
prescription pain relievers non-medically (i.e., misused) in the past
year, making it the second most misused class of drugs after marijuana
(Hughes et al., 2016). This is concerning, as continued misuse of pre-
scription pain relievers can lead to addiction, overdoses (including fatal
overdoses), and experimentation with potent, illicit opioids, such as
heroin (Alpert, Powell, & Pacula, 2018; Compton, Jones, & Baldwin,
2016; Jones, 2013). Government agencies have enacted several policies
to curb prescription pain reliever misuse, including educational efforts
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about appropriate use (US Department of Health and Human Services,
2015); prescription drug monitoring programs (Ali, Dowd, Classen,
Mutter, & Novak, 2017); opioid prescribing guidelines (Dowell,
Haegerich, & Chou, 2016); and supporting abuse-deterrent formula-
tions of prescription opioids (Cicero & Ellis, 2015; Cicero, Ellis, &
Surratt, 2012).
Abuse-deterrent opioid formulations (Opioid Abuse Deterrence,
Research, and Recovery Act of 2017, 2017) have received recent at-
tention, particularly related to their impacts on prescription pain re-
liever misuse and associated outcomes. Abuse-deterrent formulations
are intended to reduce abuse by making the drugs more tamper re-
sistant. A notable example was the 2010 reformulation of OxyContin,
which made that product more difficult to cut, crush, and dissolve
(OXYCONTIN, 2017) This innovation has received substantial policy
and research interest because of the original product’s high market
share and potential for abuse (Cicero & Ellis, 2015; Cicero et al., 2012;
Butler et al., 2013; Coplan, Kale, Sandstrom, Landau, & Chilcoat, 2013;
Havens, Leukefeld, DeVeaugh-Geiss, Coplan, & Chilcoat, 2014; Sessler
et al., 2014; Severtson et al., 2016).
Previous studies examining the impact of the reformulation found
that, as anticipated, it coincided with a significant reduction in
OxyContin misuse (Cicero et al., 2012; Coplan et al., 2013; Havens
et al., 2014; Jones, Muhuri, & Lurie, 2017; Opioid Abuse Deterrence,
Research, and Recovery Act of, 2017; Sessler et al., 2014; Severtson
et al., 2016). One notable exception to this is work by Jones and col-
leagues (Jones et al., 2017); which found no significant difference in the
prevalence of OxyContin misuse before the reformulation from 2006 to
2009 and after the reformulation in 2013. Concerns have been raised,
however, that the reformulation may have led to an unintended con-
sequence: an increase in heroin use and deaths (Alpert et al., 2018;
Cicero & Ellis, 2015; Dart et al., 2015; Evans, Lieber, & Power, 2019).
Between 2010 and 2014, the number of heroin-related deaths tripled,
(Center for Disease Control and Prevention NCfIPaC, Division of
Unintentional Injury Prevention. Opioid Data Analysis. Accessed 5/21/,
2017) and some studies have concluded that the reformulation led to a
substantial share of these deaths (Alpert et al., 2018; Evans et al.,
2019). However, many of these studies did not test the intermediate
steps necessary to link the reformulation to heroin deaths, such as
heroin initiation and use; those that did seek to address this issue relied
on small convenience samples which may not be generalizable to the
broader population (Cicero & Ellis, 2015).
Our study fills an important gap in the literature by exploring
whether the reformulation was associated with some of the inter-
mediate outcomes necessary to explain the previously hypothesized
connection to heroin deaths. We utilized data from the U.S. National
Survey on Drug Use and Health (NSDUH) to measure the nationwide
impacts of the reformulation on prescription pain reliever misuse, pain
reliever use disorder, heroin intiation, heroin use, and heroin use dis-
order among individuals with a history of OxyContin misuse. To do this,
we used a difference-in-differences methodology comparing two groups
of individuals, each with a history of misuse: inidividuals who misused
OxyContin prior to the reformulation and those who misused other
prescription pain relievers prior to the reformulation. For the group
with a history of OxyContin misuse, the drug they had misused became
more difficult to use for non-medical purposes due to the reformulation;
the group which misused other prescription pain relievers experienced
no change in their ability to use their drugs non-medically.
2. Methods
2.1. Data
Our primary data source was the 2005–2014 National Survey on
Drug Use and Health (NSDUH). The NSDUH is an annual cross-sectional
survey at the individual-level conducted by the Substance Abuse and
Mental Health Services Administration (SAMHSA) that provides
detailed information about the substance use and mental health of the
civilian, noninstitutionalized population age 12 and older in the United
States. Data on self-reported substance use includes information on past
month use, past year use, lifetime use, and age at first use. Item non-
response in the survey is addressed using a model-based statistical
imputation procedure (RTI International, 2015). More detailed in-
formation about NSDUH’s design and data collection process can be
found elsewhere (Substance Abuse and Mental Health Services
Administration, Center for Behavioral Health Statistics and Quality,
2015). We supplemented NSDUH with previously-published data on
prescription drug monitoring programs (PDMPs) (Ali et al., 2017).
Our study sample was composed of individuals age 18 and above
who reported engaging in non-medical use of any opioid or non-opioid
prescription pain reliever (the vast majority of prescription pain re-
lievers, however, are opioid-based) (Carpenter, McClellan, & Rees,
2017) prior to the introduction of the abuse-deterrent formulation of
OxyContin (i.e., in 2010 or before) based on their reported year of first
non-medical use (unadjusted n = 81,400). Non-medical use is defined
in the NSDUH as taking a drug that was not prescribed for you or taking
the drug only for the experience or feeling it caused.
2.2. Defining exposure
The intervention that we studied was the reformulation of
OxyContin from non-abuse-deterrent to its abuse-deterrent formulation.
We assume that individuals who misused non-abuse-deterrent
OxyContin were exposed to the reformulation in that the product they
had misused became more difficult to misuse. We defined exposure to
the reformulation, therefore, as reported misuse of OxyContin in any
year prior to the reformulation. To do this, we calculated the year of
first misuse of OxyContin using the individual’s current age and re-
ported age at first misuse. Any individual whose calculated year of first
misuse was prior to the reformulation was then assumed to be exposed
to the reformulation. Based on this definition of exposure, we separated
individuals into exposed and unexposed groups. The exposed group
consisted of individuals who reported first misusing OxyContin in any
year prior to and including 2010 (unadjusted n = 17,000). The un-
exposed group consisted of individuals who did not report misusing
OxyContin prior to the reformulation but who did report their first
misuse of other prescription pain relievers during this time (unadjusted
n = 64,400). Because only non-abuse-deterrent OxyContin was avail-
able prior to the reformulation in 2010, our exposed group was com-
prised of individuals who misused non-abuse-deterrent OxyContin and
our unexposed group was comprised of individuals who did not misuse
OxyContin but did misuse other prescription pain relievers prior to the
OxyContin reformulation. As such, the former group should be directly
affected by OxyContin’s reformulation while the latter group should
not.
2.3. Outcomes
We considered five dichotomous outcomes in this study based on
self-reported behavior in the twelve months prior to the interview
(i.e.the past year): prescription pain reliever misuse, prescription pain
reliever use disorder, heroin use, heroin use disorder, and heroin in-
itiation. The outcomes measuring use disorder were derived from re-
spondent answers to sets of survey questions corresponding to
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition
(DSM-IV) criteria (American Psychiatric Association, 1994; Substance
Abuse and Mental Health Services Administration, Center for
Behavioral Health Statistics and Quality, 2015). The heroin initiation
outcome equaled one if the respondent indicated using heroin for the
first time in the past year and equaled zero if the respondent indicated
never using heroin; respondents who reported using heroin more than
one year prior to the survey year were excluded from this outcome
measure.
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2.4. Covariates
We controled for demographic and socioeconomic characteristics,
including age, gender, race/ethnicity, educational attainment, and in-
come as a percentage of the federal poverty level. We also controled for
the respondent’s state of residence using state fixed effects and for
whether the respondent lives in an urban or rural area as defined by the
Census Bureau (United States Census Bureau, 2015). Finally, we con-
troled for whether there was an active PDMP in the respondent’s state
of residence at the time of interview, as these programs have been
shown to substantially affect opioid prescriptions and prescription pain
reliever misuse (Ali et al., 2017). We categorized states as having no
PDMP, a voluntary PDMP, or a PDMP with mandatory provisions re-
quiring prescribers to enroll in and/or access it when prescribing (Ali
et al., 2017).
2.5. Statistical analysis
To estimate the impact of OxyContin’s reformulation on each of our
five outcomes, we employed multivariate logistic regression under a
difference-in-differences framework. The difference-in-differences fra-
mework compared changes in outcomes over time between the exposed
group and the unexposed group. The difference in those changes is
interpreted as the net impact of the intervention on the exposed group
relative to the unexposed group.
To estimate the model, we regressed the individual’s self-reported
outcome (e.g. whether or not the individual used heroin in the
12 months prior to the survey interview) on our exposure indicator (i.e.,
OxyContin misuse prior to the reformulation), an indicator for the post-
reformulation period (i.e., 2011–2014), and the interaction between
those two indicators, controlling for the covariates discussed above. The
estimated coefficient on the interaction term captured the net impact of
OxyContin’s reformulation for individuals who were exposed to the
original, non-abuse-deterrent formulation of OxyContin relative to
those who were not exposed to the original OxyContin but who did
have a history of other prescription pain reliever misuse.
While the difference-in-differences approach is often used with
longitudinal data, its application to pooled cross-sectional data, such as
the NSDUH, is well established in the literature 28-31 (Buckley &
Shang, 2003; Chatterji et al., 2010; Hong, 2013; Rudasingwa, Soeters, &
Basenya, 2017; Rudd, Aleshire, Zibbell, & Matthew, 2016). When using
this approach with pooled cross-sectional data, one key assumption
upon which the validity of difference-in-differences estimation relies is
that neither the exposed nor the unexposed group may experience
disproportional compositional changes in the sample over time. We
examined the distributions of characteristics over time graphically and
tested for compositional change by regressing individual characteristics
on our policy variables and found no evidence of observable composi-
tional changes that could bias our results. We also examined pre-re-
formulation trends to ensure that the parallel trends assumption was
satisfied, conducted a falsification test using an alternative policy im-
plementation date, estimated our models without controls, and esti-
mated the models with clustered standard errors rather than survey-
adjusted standard errors. Our results were robust to these alternative
specifications. More details on the models and tests of their underlying
assumptions may be found in the Supplementary Appendix.
We also estimated a set of event study models similar to the dif-
ference-in-differences model described above but replacing the single
indicator for the post-reformulation period with a set of indicators re-
presenting each survey year in our data. In these event study models,
the coefficient estimates on the interactions between our exposure in-
dicator and the indicator for each survey year provide estimates of the
impact of the OxyContin reformulation in each individual year.
We conducted all analyses in Stata 15 using the svy prefix to ac-
count for survey weights and sampling design (McClellan et al., 2018).
The analysis weights in NSDUH were constructed through a multistage
process and represent the inverse probability of selection at each
sampling stage (i.e., household selection, respondent selection),
Table 1
Mean Descriptive Characteristics of Adults in Sample, by Exposure and Time Period.
Pre-Reformulation (Survey Years 2005 – 2010) Post-Reformulation (Survey Years 2011 – 2014)
Exposed Group
(N = 10,200)
Unexposed Group
(N = 42,000)
P-value Exposed Group
(N = 6,800)
Unexposed Group
(N = 22,400)
P-value
Age 31.061
(13.075)
37.656
(13.219)
< 0.001 34.065
(12.567)
40.576
(12.807)
<0.001
Male 0.627 0.549 < 0.001 0.637 0.553 <0.001
White, non-Hispanic 0.859 0.751 < 0.001 0.845 0.714 <0.001
Black, non-Hispanic 0.039 0.088 < 0.001 0.036 0.098 <0.001
Other, non-Hispanic 0.036 0.044 < 0.001 0.041 0.053 <0.001
Hispanic 0.065 0.118 < 0.001 0.078 0.135 <0.001
Less than High School Degree 0.174 0.154 < 0.001 0.152 0.134 <0.001
High School Degree 0.327 0.308 < 0.001 0.312 0.288 <0.001
Some College/Assoc. Degree 0.332 0.294 < 0.001 0.338 0.307 <0.001
College Degree 0.104 0.133 < 0.001 0.120 0.148 <0.001
Graduate/Professional Degree 0.062 0.111 < 0.001 0.078 0.123 <0.001
Percent of Federal Poverty Level 308.143 (266.879) 345.798 (233.557) < 0.001 284.974 (221.188) 320.287 (203.802) <0.001
Lives in Urban County 0.846 0.851 0.483 0.836 0.858 0.003
State has no PDMP 0.475 0.484 0.001 0.144 0.114 <0.001
State has Voluntary PDMP 0.497 0.499 0.001 0.614 0.668 <0.001
State Requires Prescribers to Access PDMP 0.007 0.006 0.001 0.106 0.097 <0.001
State Requires Prescribers to Enroll in PDMP 0.020 0.011 0.001 0.058 0.066 <0.001
State Requires PDMP Access and Enrollment 0.000 0.000 – 0.079 0.055 <0.001
Past Year Prescription Pain Reliever Misuse 0.558 0.297 < 0.001 0.419 0.238 <0.001
Past Year Prescription Pain Reliever Use Disorder 0.154 0.030 < 0.001 0.146 0.030 <0.001
Past Year Heroin Use 0.056 0.005 < 0.001 0.074 0.007 <0.001
Past Year Heroin Use Disorder 0.036 0.003 < 0.001 0.057 0.004 <0.001
Past Year Heroin Initiation 0.017 0.001 < 0.001 0.017 0.002 <0.001
Means (SD in parentheses) adjusted for survey design and weights. Survey-adjusted F-tests for differences between groups. The exposed group consists of individuals
who misused OxyContin prior to the reformulation. The unexposed group consists of individuals who did not misuse OxyContin, but did misuse other prescription
pain relievers, prior to the reformulation. Each individual is observed in only one survey year.
SD – Standard Deviation.
PDMP – Prescription Drug Monitoring Program.
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adjustments for nonresponse and extreme weights, and poststratifica-
tion to known population data (i.e., from the U.S. Census) (RTI
International. (2015), 2015). The use of these weights and accounting
for the sampling design produced estimates that are nationally re-
presentative.
3. Results
The demographic and socioeconomic characteristics of our sample
are shown in Table 1. The composition of our exposed and unexposed
groups was generally stable over time, as were the differences between
them. While the prevalence of PDMPs increased after the reformulation,
similar changes occurred in both groups. We observed some differences
between the groups within the two periods: individuals in our exposed
group were younger and were more likely to be male, white, have no
college degree, and to be poorer. We adjusted for these observed dif-
ferences in the multivariate logistic regression.
The key results from our difference-in-differences framework are
shown in Table 2. The full results and sensitivity analyses are shown in
the Supplementary Appendix. We found that misuse of prescription
pain relievers declined in both the exposed and the unexposed groups,
but the decline was greater in the exposed group relative to the un-
exposed group. Specifically, the exposed group had 21 percent lower
odds of misusing prescription pain relievers after the reformulation
than the unexposed group (OR: 0.791, CI: 0.694–0.902, p < 0.001).
Similarly, although heroin initiation increased in both groups, the in-
crease was smaller in the exposed group than in the unexposed group.
We found that the odds of heroin initiation in the exposed group were
58 percent lower than the unexposed group (OR: 0.422, CI:
0.218–0.818, p = 0.011). We found no statistically significant effect of
the reformulation on the exposed group relative to the unexposed group
for prescription pain reliever use disorder (OR: 0.934, CI: 0.756–1.153,
p = 0.524), heroin use (OR: 1.014, CI: 0.697–1.476, p = 0.941), and
heroin use disorder (OR: 1.063, CI: 0.657–1.718, p = 0.804). Our
sensitivity analyses broadly confirm these results; details are provided
in the Supplementary Appendix.
In Fig. 1, we present odds ratios estimated from the event study
models for the exposed group relative to the unexposed group for each
outcome variable in each year. For the years after the reformulation,
the results confirm our findings from our difference-in-differences fra-
mework and demonstrate that the impact of the reformulation on the
exposed group appears to have grown over time for prescription pain
reliever misuse while being steady over time for heroin initiation. For
the other outcome measures, we continued to find that the reformula-
tion had no statistically significant impact on the exposed group re-
lative to the unexposed group.
4. Discussion
Mitigating the rise in prescription pain reliever misuse requires
policies that can address the numerous paths leading to this behavior.
Three possible outcomes that might justify a role for abuse-deterrent
opioids include: (1) discouraging users of prescription pain relievers
from misusing these products; (2) reducing the likelihood that existing
prescription pain reliever misusers transition into use disorders; and,
consequently (3) preventing the transition from prescription pain re-
lievers to illicit opioids, such as heroin. Our analysis provides three
findings that collectively suggest that the reformulation of OxyContin
was associated with a reduction in the misuse of prescription pain re-
lievers among those with a history of OxyContin misuse and that it was
not associated with relatively greater increases in heroin initiation or
the likelihood of heroin use among this group.
Our first major finding is that the reformulation of OxyContin was
associated with a net reduction in the misuse of prescription pain re-
lievers among those who misused OxyContin prior to the reformulation.
While both the exposed and unexposed groups experienced a decline in
prescription pain reliever misuse following the reformulation, that de-
cline was greater for the exposed group. We estimate that individuals
who had misused OxyContin prior to the reformulation experienced a
cumulative 21 percent reduction in the odds of misuse over the first
three years following the reformulation relative to the unexposed
group, and this impact appears to have increased over time. These re-
sults suggest that some individuals no longer misused any prescription
pain relievers once it became more difficult to tamper with OxyContin.
Our second major finding is that the reformulation appears not to be
associated with a net change in the incidence of prescription pain re-
liever use disorder, heroin use disorder, or heroin use among those with
a history of pre-reformulation OxyContin misuse. Although abuse-de-
terrent OxyContin is more difficult to cut, crush, and dissolve compared
with the original extended-release product (OXYCONTIN, 2017), there
are still ways for individuals to circumvent these properties (Cicero &
Ellis, 2015). This result, combined with our first major finding, suggests
that the reformulation may have discouraged some from misusing
prescription pain relievers, but it may not have impacted the likelihood
Table 2
Estimating the Effects of the OxyContin Reformulation: Odds Ratios from Models for Prescription Pain Reliver Misuse and Use Disorder and Heroin Use, Use Disorder,
and Initiation Outcomes, Difference-in-Difference Framework.
Outcome Measures Past Year Prescription Pain
Reliever Misuse
Past Year Prescription Pain
Reliever Use Disorder
Past Year Heroin Use Past Year Heroin Use
Disorder
Past Year Heroin
Initiation,
Exposure 2.683*** 5.349*** 9.547*** 11.536*** 10.875***
[2.479,2.905] [4.705,6.081] [7.159,12.733] [8.117,16.394] [7.083,16.696]
(< 0.001) (< 0.001) (< 0.001) (< 0.001) (< 0.001)
Post-reformulation 0.808*** 1.055 1.300 1.373 2.654***
[0.753,0.868] [0.896,1.243] [0.923,1.832] [0.883,2.137] [1.502,4.690]
(< 0.001) (0.517) (0.134) (0.160) (0.001)
Exposure × Post-reformulation 0.791*** 0.934 1.014 1.063 0.422**
[0.694,0.902] [0.756,1.153] [0.697,1.476] [0.657,1.718] [0.218,0.818]
(< 0.001) (0.524) (0.941) (0.804) (0.011)
Observations 81,400 81,400 80,600 79,700 72,800
Survey-adjusted odds ratios from logit regressions with confidence intervals presented in brackets and P-values in parentheses. “Exposure” is an indicator for
OxyContin misuse prior to the reformulation, and “Post-reformulation” is an indicator for individuals surveyed after the reformulation (i.e. 2011–2014 survey years).
The reference group is made up of those individuals who did not misuse OxyContin prior to the reformulation.
Reformulation date set at 1/1/2011.
* P < 0.10, ** P < 0.05, *** P < 0.01.
x – Indicates interaction term.
All models control for age, age squared, gender, race/ethnicity, education, income, urbanicity, state PDMP policy, and state of residence (implemented as state-level
fixed effects). See Supplementary Appendix for full results.
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of prescription pain reliever misuse or heroin use among those ex-
periencing the more severe use disorders, at least in the first few years
following the reformulation.
Our third major finding is that, while heroin initiation rose in both
groups following the reformulation, the implementation of abuse-de-
terrent OxyContin appears to be associated with relatively lower heroin
initiation for the exposed group; all else constant, the unexposed group
experienced a larger increase in heroin initiation than did the exposed
group. We estimate that individuals who had misused OxyContin prior
to the reformulation experienced a 58 percent reduction in the odds
that they initiated heroin after the reformulation compared to those
who had misused other prescription pain relievers, with much of this
impact occurring at least two years after the reformulation. This result
suggests that the reformulation did not lead those who had previously
misused OxyContin to more frequently begin using heroin relative to
those who had misused other prescription pain relievers.
Combined, our results suggest that the reformulation did not in-
crease the likelihood that OxyContin misusers would use heroin, either
among new or existing heroin users. To the extent that misuse of pre-
scription pain relievers may have led to heroin use prior to the
OxyContin reformulation, the likelihood of that transition did not seem
to increase because of the reformulation. While previous studies have
suggested that the reformulation led to increases in heroin deaths
(Alpert et al., 2018; Cicero & Ellis, 2015; Coplan et al., 2013; Dart et al.,
2015), our results suggest that any increase that occurred was likely not
due to individuals switching from OxyContin to heroin. If this had been
the case, we would expect to observe increases in the odds of heroin
initiation and heroin use. Our results, however, suggest the opposite:
that the reformulation was associated with a relatively smaller increase
in the odds of heroin initiation and no statistically significant change in
the odds of heroin use or use disorder among those who misused
OxyContin prior to the reformulation. Previous studies only analyzed
trends in final outcomes, such as heroin deaths, and lacked the in-
dividual-level data to link OxyContin misuse with heroin-related deaths
in any given individual. Other concurrent trends may have contributed
to observed increases in heroin deaths during this time period; ex-
amples include the greater availability of heroin, lower heroin prices,
changes in the quantity of heroin being used, and the increased potency
of illicit opioids due to the expanded use of fentanyl and its analogues
(Compton et al., 2016; Rudd et al., 2016). More research needs to be
done to understand the relationship between these trends and the rising
heroin death rate in the post-reformulation period.
We obtained our results by implementing a difference-in-differences
approach which included a group that we hypothesize was not exposed
to the reformulation. This method allowed us to remove the effects of
factors that impacted both groups simultaneously or that were constant
over time within each group. We also controled for PDMPs as well as
unobserved factors that varied across states but were constant over time
using the restricted NSDUH dataset with state identifiers.
Our study has a few limitations. First, rather than measuring the
same individuals over time, our data consist of repeated cross-sections
containing different individuals in each year. While we did control for
observed individual-level differences and found no evidence of ob-
served differential changes in the sample composition, we were unable
to account for unobserved individual-level differences or differential
changes in sample composition that may have influenced the outcomes,
including any triggered by the OxyContin reformulation. Second, the
reformulation could have indirectly affected our unexposed group if it
contributed to changes in, for example, the prices or insurance coverage
of other prescription pain relievers, which could have either increased
Fig. 1. Estimating Effects of the OxyContin Reformulation in Each Individual Year: Odds Ratios from Event Study Models for Prescription Pain Reliver Misuse and
Use Disorder, and Heroin Use, Use Disorder and Initiation Outcomes. Survey-adjusted odds ratios with confidence interval bars for the interaction between exposure
to the OxyContin reformulation and survey year. The year 2011 represents zero years since the reformulation. All models control for age, age squared, gender, race/
ethnicity, education, income, urbanicity, state PDMP policy, and state of residence (implemented as state-level fixed effects).
C. Wolff, et al. Addictive Behaviors 105 (2020) 106268
5
or decreased our estimated impacts. Third, our approach made use of
survey data that excluded people who were homeless or in-
stitutionalized and relied on self-reported measures of drug use. Both
characteristics may have produced underestimates of heroin initiation
and use, and our findings of the impact of the reformulation may not be
generalizable to certain high-risk groups excluded from the NSDUH
sampling frame. Finally, our study may not be generalizable to other
abuse-deterrent opioids, particularly if they have lower market shares
than OxyContin or are entering markets that are already partly satu-
rated with other abuse-deterrent products.
Evidence indicates that abuse-deterrent formulations of prescription
opioids are an important part of a broader public health strategy for
addressing the opioid crisis. Additional efforts are needed to help the
approximately two million people with existing opioid use disorders;
interventions might include increasing the availability of naloxone and
the utilization of medication-assisted treatment (MAT). Previous re-
search has found that naloxone access laws and Good Samaritan laws
are potentially associated with lower incidence of opioid-overdose
mortality (McClellan et al., 2018). While MAT has been demonstrated
to be effective at treating patients with opioid use disorder, it is un-
derutilized from a clinical perspective (Naeger et al., 2016; Saloner &
Barry, 2018). As additional approaches to addressing the opioid crisis
are proposed, it will be important to subject them to similarly rigorous
evaluation and to identify potential opportunities to implement them
on a broader scale (Sharfstein, 2018).
This research is particularly timely for policymakers, who have been
tasked with increasing the prevalence of abuse-deterrent opioids in the
marketplace (Administration FaD, 2018) while they face scrutiny over
whether these products are cost-effective and whether unintended risks
might offset intended benefits (Becker and Fiellin, 2017). Our results
suggest that expanding access to abuse-deterrent opioids might provide
further contributions towards addressing prescription pain reliever
misuse as part of a comprehensive strategy for combating the opioid
crisis without contributing to new heroin use.
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